MichaÅ, OtrÄba

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5995826/publications.pdf

Version: 2024-02-01

37	578	623574	677027
papers	citations	14 h-index	22 g-index

42	42	42	596
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Antiviral activity of chlorpromazine, fluphenazine, perphenazine, prochlorperazine, and thioridazine towards RNA-viruses. A review. European Journal of Pharmacology, 2020, 887, 173553.	1.7	47
2	Interaction between ciprofloxacin and melanin: The effect on proliferation and melanization in melanocytes. European Journal of Pharmacology, 2011, 669, 32-37.	1.7	36
3	Comparison of the Antioxidant Activity of Propolis Samples from Different Geographical Regions. Plants, 2022, 11, 1203.	1.6	36
4	In vitro anticancer activity of fluphenazine, perphenazine and prochlorperazine. A review. Journal of Applied Toxicology, 2021, 41, 82-94.	1.4	32
5	Effect of norfloxacin and moxifloxacin on melanin synthesis and antioxidant enzymes activity in normal human melanocytes. Molecular and Cellular Biochemistry, 2015, 401, 107-114.	1.4	31
6	Cytotoxic effect of lomefloxacin in culture of human epidermal melanocytes. Pharmacological Reports, 2013, 65, 689-699.	1.5	28
7	Modulation of melanogenesis and antioxidant defense system in melanocytes by amikacin. Toxicology in Vitro, 2013, 27, 1102-1108.	1.1	28
8	Modulation of Melanogenesis and Antioxidant Status of Melanocytes in Response to Phototoxic Action of Doxycycline. Photochemistry and Photobiology, 2015, 91, 1429-1434.	1.3	23
9	Effect of tetracycline and UV radiation on melanization and antioxidant status of melanocytes. Journal of Photochemistry and Photobiology B: Biology, 2015, 148, 168-173.	1.7	22
10	Effect of streptomycin on melanogenesis and antioxidant status in melanocytes. Molecular and Cellular Biochemistry, 2013, 383, 77-84.	1.4	19
11	Impact of sparfloxacin on melanogenesis and antioxidant defense system in normal human melanocytes HEMa-LP â€“ An in vitro study. Pharmacological Reports, 2015, 67, 38-43.	1.5	17
12	Nicotine impact on melanogenesis and antioxidant defense system in HEMn-DP melanocytes. Molecular and Cellular Biochemistry, 2014, 395, 109-116.	1.4	16
13	Melanogenesis and antioxidant defense system in normal human melanocytes cultured in the presence of chlorpromazine. Toxicology in Vitro, 2015, 29, 221-227.	1.1	16
14	Impact of kanamycin on melanogenesis and antioxidant enzymes activity in melanocytesâ€”an in vitro study. Journal of Cellular Biochemistry, 2013, 114, 2746-2752.	1.2	14
15	Effect of thioridazine on antioxidant status of HEMn-DP melanocytes. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 1097-1104.	1.4	14
16	Polyphenolsâ€™ Cardioprotective Potential: Review of Rat Fibroblasts as Well as Rat and Human Cardiomyocyte Cell Lines Research. Molecules, 2021, 26, 774.	1.7	14
17	Effect of fluoroquinolones on melanogenesis in normal human melanocytes HEMn-DP: a comparative in vitro study. Cutaneous and Ocular Toxicology, 2017, 36, 169-175.	0.5	13
18	Phototoxic effect of oxytetracycline on normal human melanocytes. Toxicology in Vitro, 2018, 48, 26-32.	1.1	13

#	Article	IF	Citations
19	EPR spectroscopy of chlorpromazine-induced free radical formation in normal human melanocytes. European Biophysics Journal, 2015, 44, 359-365.	1.2	12
20	Effect of nicotine on melanogenesis and antioxidant status in HEMn-LP melanocytes. Environmental Research, 2014, 134, 309-314.	3.7	10
21	Eâ€cigarettes: voltageâ€and concentrationâ€dependent loss in human lung adenocarcinoma viability. Journal of Applied Toxicology, 2018, 38, 1135-1143.	1.4	10
22	Antimelanoma activity of perphenazine and prochlorperazine in human COLO829 and C32 cell lines. Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392, 1257-1264.	1.4	9
23	Perphenazine and prochlorperazine induce concentration-dependent loss in human glioblastoma cells viability. Die Pharmazie, 2018, 73, 19-21.	0.3	9
24	The effect of simultaneous exposure of HEMn-DP and HEMn-LP melanocytes to nicotine and UV-radiation on the cell viability and melanogenesis. Environmental Research, 2016, 151, 44-49.	3.7	7
25	Cardioprotective Activity of Selected Polyphenols Based on Epithelial and Aortic Cell Lines. A Review. Molecules, 2020, 25, 5343.	1.7	7
26	Prochlorperazine interaction with melanin and melanocytes. Die Pharmazie, 2017, 72, 171-176.	0.3	7
27	In vitro melanogenesis inhibition by fluphenazine and prochlorperazine in normal human melanocytes lightly pigmented. DARU, Journal of Pharmaceutical Sciences, 2018, 26, 85-89.	0.9	6
28	Impact of lomefloxacin on antioxidant enzymes activity in normal melanocytes HEMa-LP. Current Issues in Pharmacy and Medical Sciences, 2012, 25, 426-429.	0.1	6
29	Gentamicin affects melanogenesis in normal human melanocytes. Cutaneous and Ocular Toxicology, 2015, 34, 107-111.	0.5	4
30	Bee Venom, Honey, and Royal Jelly in the Treatment of Bacterial Infections of the Oral Cavity: A Review. Life, 2021, 11, 1311.	1.1	4
31	FLUPHENAZINE AND PERPHENAZINE IMPACT ON MELANOGENESIS AND ANTIOXIDANT ENZYMES ACTIVITY IN NORMAL HUMAN MELANOCYTES. Acta Poloniae Pharmaceutica, 2016, 73, 903-911.	0.3	4
32	Viability of Human Melanocytes HEMa-LP Exposed to Amikacin and Kanamycin. Indian Journal of Pharmaceutical Sciences, 2013, 75, 102.	1.0	3
33	Netilmicin-induced modulation of melanogenesis in HEMa-LP melanocytes. Acta Poloniae Pharmaceutica, 2013, 70, 803-8.	0.3	3
34	EFFECT OF PARACETAMOL ON MELANIZATION PROCESS IN HUMAN EPIDERMAL MELANOCYTES. Acta Poloniae Pharmaceutica, 2016, 73, 653-8.	0.3	3
35	A Small Molecule Targeting Human MEK1/2 Enhances ERK and p38 Phosphorylation under Oxidative Stress or with Phenothiazines. Life, 2021, 11, 297.	1.1	2
36	The impact of ketoprofen on viability and melanization process in normal melanocytes HEMn-DP. Current Issues in Pharmacy and Medical Sciences, 2012, 25, 376-380.	0.1	2

#	Article	IF	Citations
37	Perphenazine and prochlorperazine decrease glioblastoma Uâ€‘87 MG cell migration and invasion: Analysis of the ABCB1 and ABCG2 transporters, Eâ€‘cadherin, Î±â€‘tubulin and integrins (Î±3, Î±5, and Î²1) levels. Oncology Letters, 2022, 23, 182.	0.8	2